Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Arriola C.S.; Soto G.; Westercamp M.; Bollinger S.; Espinoza A.; Grogl M.; Llanos-Cuentas A.; Matos E.; Romero C.; Silva M.; Smith R.; Olson N.; Prouty M.; Azziz-Baumgartner E.; Lessa F.C. · Emerging Infectious Diseases (2022) · DOI: 10.3201/eid2813.212477

Resumen

In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.